New hope for HAE sufferers: Long-Term drug trial launches
NCT ID NCT07204938
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This study tests the long-term safety and effectiveness of a drug called navenibart for people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling. It is for adults and teens who were in a previous navenibart study. Participants will receive navenibart, and some may later get a personalized dose. The goal is to see if the drug can keep preventing swelling attacks over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 2
Scottsdale, Arizona, 85251, United States
Conditions
Explore the condition pages connected to this study.